We Offer Worldwide Shipping
Login Wishlist

Ophiogenin 3-O-α-L-rhamnopyranosyl(1→2)[β-D-xylopyranosyl(1→3)]-β-D-glucopyranoside

$504

Brand : BIOFRON
Catalogue Number : BD-P0029
Specification : 98.0%(HPLC)
CAS number : 288143-27-1
Formula : C44H70O18
Molecular Weight : 887.02
PUBCHEM ID : 102004869
Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0029

Analysis Method

Specification

98.0%(HPLC)

Storage

-20℃

Molecular Weight

887.02

Appearance

Powder

Botanical Source

This product is isolated and purified from the roots of Ophiopogon japonicus

Structure Type

Category

SMILES

CC1CCC2(C(C3(C(O2)CC4(C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)OC8C(C(C(CO8)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)O)O)C)OC1

Synonyms

IUPAC Name

Density

1.5±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

XEMVQWDHRXAQNR-YVEJFGEMSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:288143-27-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30760242

Abstract

Background
Disrupted sleep rhythms may lead to cancer development. We conducted a population-based cohort study to evaluate the incidence and risk of prostate cancer in patients with sleep disorders (SDs).

Methods
Patients newly diagnosed with SDs between 2000 and 2010 were enrolled from the Taiwan Longitudinal Health Insurance Database. A non-SD cohort age-matched (5-y intervals), comorbidities, and medications was randomly sampled from the general population at a 1:1 ratio. The follow-up period extended from the index date of SDs to the diagnosis of prostate cancer, censoring, or the end of 2013. We used Cox proportional hazards models to calculate the risk of prostate cancer.

Results
In total, 41,444 patients were enrolled in each cohort. The mean age of the SD cohort was 48.0 years and that of the non-SD cohort was 47.8 years, with 58.2% of both cohorts aged younger than 50 years. The incidence of prostate cancer increased with age. The overall incidence of prostate cancer was higher in the SD cohort than in the non-SD cohort (9.56 vs 6.36 per 10,000 person-y), with an adjusted hazard ratio of 1.42 (95% CI = 1.20-1.69). Age-specific analysis revealed a 1.35-fold increased risk of prostate cancer in the patients aged ≥65 years in the SD cohort compared with the non-SD counterparts (95% CI = 1.10-1.65).

Conclusions
Patients with SDs are associated with increased risk of prostate cancer.

KEYWORDS

Sleep disorders (SDs), Prostate cancer, Cohort study

Title

Sleep disorders associated with risk of prostate cancer: a population-based cohort study

Author

Wei-Sheng Chungcorresponding author1,2,3 and Cheng-Li Lin4,5

Publish date

2019